CSPC Group announced that the new class 1 chemical drug SYH2046 tablets developed by the Group have been approved by the US Food and Drug Administration and can conduct clinical trials in the US. The product was also approved by the State Drug Administration of the People's Republic of China in April 2025, and clinical trials can be carried out in China. SyH2046 tablets are a first-in-class small-molecule drug with a new structure with completely independent intellectual property rights. The approved clinical trial indication is heart failure after acute myocardial infarction.

CSPC Group announced that the new class 1 chemical drug SYH2046 tablets developed by the Group have been approved by the US Food and Drug Administration and can conduct clinical trials in the US. The product was also approved by the State Drug Administration of the People's Republic of China in April 2025, and clinical trials can be carried out in China. SyH2046 tablets are a first-in-class small-molecule drug with a new structure with completely independent intellectual property rights. The approved clinical trial indication is heart failure after acute myocardial infarction.